10-Q: Amwell Narrows Losses, Boosts Subscription Revenue in Q3

Amwell reported a significant reduction in net loss and improved Adjusted EBITDA for Q3 and the first nine months of 2025, driven by strategic cost-cutting and increased subscription revenue.

Summary

• Net loss attributable to American Well Corporation improved by 26% to $(32.38) million for the three months ended September 30, 2025, compared to $(43.46) million in the prior year.
• For the nine months ended September 30, 2025, net loss improved by 57% to $(70.78) million, down from $(165.49) million in the same period last year.
• Adjusted EBITDA improved to $(12.67) million for Q3 2025, a significant improvement from $(31.01) million in Q3 2024.
• Nine-month Adjusted EBITDA improved to $(29.58) million, compared to $(111.62) million for the same period in 2024.
• Total revenue for Q3 2025 decreased by 8% to $56.29 million, from $61.05 million in Q3 2024.
• Total revenue for the nine months ended September 30, 2025, increased by 6% to $194.02 million, from $183.36 million in the prior year.
• Subscription revenue increased by $25.0 million to $103.57 million for the nine months ended September 30, 2025, driven by strategic customer arrangements.
• Visit revenue decreased by $17.5 million to $70.57 million for the nine months ended September 30, 2025, primarily due to the sale of the APC Business and lower urgent care/behavioral health visit volumes.
• Operating expenses decreased significantly, with total costs and operating expenses down 21% in Q3 and 23% for the nine months ended September 30, 2025, largely due to headcount reductions and cost savings measures.
• Cash and cash equivalents stood at $200.89 million as of September 30, 2025, a decrease from $228.32 million at December 31, 2024.
• The company completed the divestiture of its APC Business on January 8, 2025, recognizing a net gain of $8.71 million.
• The joint venture CCAW, JV LLC with Cleveland Clinic is undergoing complete liquidation and dissolution, expected to conclude by March 31, 2026.
• Made a minority investment of $1.0 million in Aingelz, Inc. for artificial intelligence development on March 11, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to incur net losses, the significant year-over-year improvements in net loss and Adjusted EBITDA, driven by aggressive cost-cutting and strategic divestitures, indicate a positive trajectory towards profitability. Growth in subscription revenue is also a strong positive. However, the overall Q3 revenue decline and continued cash burn, along with increased legal costs, temper the optimism.

Positives

• Significant improvement in net loss, reducing by 26% in Q3 and 57% for the nine months ended September 30, 2025, indicating effective cost management.
• Adjusted EBITDA showed substantial improvement, reducing from $(31.01) million to $(12.67) million in Q3 and from $(111.62) million to $(29.58) million for the nine-month period.
• Subscription revenue increased by $25.0 million for the nine months ended September 30, 2025, demonstrating growth in the core platform business.
• Total costs and operating expenses decreased by 21% in Q3 and 23% for the nine-month period, reflecting successful strategic transformation actions and headcount reductions across all operational areas.
• The divestiture of the APC Business generated a net gain of $8.71 million and allows for a focused strategy on the Converge platform and profitability.
• Cash used in operating activities significantly decreased to $(48.60) million for the nine months ended September 30, 2025, compared to $(113.90) million in the prior year, indicating improved operational efficiency.

Negatives

• Total revenue for the three months ended September 30, 2025, decreased by 8% year-over-year.
• Visit revenue declined by $17.5 million for the nine months ended September 30, 2025, partly due to the APC divestiture and lower urgent care/behavioral health volumes.
• The company continues to operate at a net loss and has an accumulated deficit of over $2.0 billion as of September 30, 2025.
• Cash and cash equivalents decreased by $27.43 million from December 31, 2024, to September 30, 2025.
• Legal costs increased by $5.2 million in Q3 and $8.0 million for the nine months ended September 30, 2025, related to ongoing legal matters.

Risks

• Weak growth and increased volatility in the digital care market could hinder future performance.
• The company has a history of losses and may not achieve profitability in the future.
• Inability to adapt to rapid technological changes could impact competitiveness.
• Reliance on a limited number of significant clients poses a risk if business from these clients is lost.
• Increased competition from existing and potential new participants in the healthcare industry.
• Changes in healthcare laws, regulations, or trends, and the ability to operate in a heavily regulated industry.
• Compliance with regulations concerning personally identifiable information and personal health information, with significant liability potential from cybersecurity breaches.
• Slower than expected growth in patient adoption of digital care and platform usage by clients or patients.
• Inability to grow the base of affiliated and non-affiliated providers sufficient to serve patient demand.
• Challenges in commencing and completing strategic transformation initiatives and their potential impact.
• Difficulties in establishing and maintaining strategic relationships with third parties.
• Impact of seasonal viruses on business or financial outlook forecasting.
• Insurance maintained may not fully cover all potential exposures.
• Uncertainty regarding the continuation of the Defense Health Agency relationship beyond July 2026 with comparable financial terms.

Future Outlook

The company expects research and development and sales and marketing expenses to decrease in the current year and then remain flat in future periods. General and administrative expenses are also expected to decrease in the current year and then remain relatively flat, based on cost savings measures. The company believes its existing cash and cash equivalents will be sufficient to meet working capital and capital expenditure needs for at least the next 12 months. However, future capital requirements depend on growth rate, contract renewals, platform consultations, product development, sales and marketing expansion, new service offerings, and market acceptance of digital care. The company may need to seek additional equity or debt financing in the future.

Management Comments

• "We divested the APC Business as it was determined the offering no longer fit our goals around profitability and growth. Streamlining our service offerings will enable us to focus our resources on the Converge platform, strategic customers, and our path to profitability."
• "We believe increased spending in prior years was a temporary investment to accelerate development of a more scalable and economically beneficial solution that will properly position the Company to benefit in the long term and have seen marked decline during 2025 as we return to normal levels of spend in future periods."
• "Our strategic transformation actions include transformational consulting, headcount reductions, and other related transitional amounts to maintain our competitive footprint."

Industry Context

Amwell's focus on its Converge platform and hybrid care delivery aligns with the broader healthcare industry trend towards integrated virtual and in-person care models. The divestiture of the APC Business indicates a strategic shift towards core platform offerings and away from less profitable service lines, a common move for companies seeking to optimize their business model in a competitive and evolving digital health market. The decline in overall visit volumes, while partly due to divestiture, also reflects potential market saturation or increased competition in certain virtual care segments, contrasting with the growth in subscription revenue which suggests a strong demand for underlying platform technology.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• No pending claims, charges, or litigation that are expected to have a material adverse effect on the company's consolidated financial position, results of operations, or cash flows.
• Legal costs increased by $5.2 million in Q3 2025 and $8.0 million for the nine months ended September 30, 2025, related to diligence and discovery for various ongoing legal matters.

Related Party Transactions

• Revenue from Cleveland Clinic (a related party due to a board member) was $177k for Q3 2025 and $306k for 9M 2025.
• Revenue from CCAW, JV LLC (a joint venture with Cleveland Clinic) was $567k for Q3 2025 and $1,703k for 9M 2025. The joint venture is being liquidated.

Stakeholder Impact

• **Shareholders:** Potential for improved long-term value due to reduced losses, strategic focus on core platform, and cost efficiencies. However, continued losses and potential future capital raises could dilute existing shares.
• **Employees:** Significant headcount reductions (29% in cost of revenue, 15% in R&D, 49% in sales & marketing, 36% in G&A for Q3 YoY) indicate job insecurity for some, while remaining employees may face increased workload or pressure. Executive compensation is tied to performance goals.
• **Customers:** Focus on the Converge platform aims to provide an improved and more robust healthcare solution, potentially enhancing service quality and integration capabilities. Divestiture of APC Business means certain telepsychiatry services will no longer be directly offered by Amwell.
• **Suppliers/Partners:** Strategic relationships are crucial for the Converge platform's success and expansion. The investment in Aingelz, Inc. indicates a commitment to AI development, potentially benefiting technology partners.
• **Creditors:** Improved cash flow from operations and reduced net losses, along with no outstanding debt, suggest a stronger financial position, reducing credit risk.

Next Steps

• Continue to evaluate the impact of the newly enacted One Big Beautiful Bill Act (OBBBA) on the forecasted annual effective tax rate in future periods.
• Complete the liquidation and dissolution of the CCAW, JV LLC joint venture by March 31, 2026.
• Continue to evaluate potential strategic transformation actions and may incur additional related costs in future periods.
• Focus resources on the Converge platform and strategic customers to achieve profitability.
• Monitor and manage the vesting of executive performance-based awards tied to annual goals and operating cash flow through December 31, 2027.

Key Dates

Recommendation

Amwell's Q3 2025 filing shows a clear commitment to improving financial performance through aggressive cost management and strategic focus on its core Converge platform. The significant reduction in net loss and Adjusted EBITDA, coupled with growth in subscription revenue, are positive indicators. However, the company still operates at a substantial net loss and faces ongoing challenges in overall revenue growth and visit volumes. The need for potential future capital raises also presents a risk of dilution. While the strategic direction is sound, the company is still in a transitional phase towards sustained profitability. A 'hold' recommendation is appropriate as investors should monitor the execution of these strategic initiatives and the company's ability to achieve consistent positive cash flow and profitability before considering a 'buy' position.

Keywords

Telehealth, Digital Health, Virtual Care, Healthcare Technology, Amwell Converge, SEC Filing, 10-Q, Financial Results, Subscription Revenue, Adjusted EBITDA, Cost Reduction, Strategic Transformation, Performance Share Units, Restricted Stock Units, Executive Compensation